The Benefits of Residual Hair Cell Function for Speech and Music Perception in Pediatric Bimodal Cochlear Implant Listeners
Table 1
CI subject demographic information.
Subject
Etiology
Gender
Age at testing (yrs)
Age at CI (yrs)
Dur deaf (yrs)
CI exp (yrs)
HA exp (yrs)
CI device
CI strategy
Aided PTA dB HL
Unaided PTA dB HL
S1
Unknown
F
9.2
4.0
4.0
5.2
1.00
AB HiRes 90K
F120
36.7
70.0
S2
Unknown
M
7.3
3.1
3.1
4.2
3.80
Cochlear N-24
ACE
45.0
70.0
S3
LVAS
F
5.0
3.0
2.0
1.0
2.00
Cochlear N-24
ACE
40.0
73.3
S4
Unknown
M
10.0
5.0
5.0
5.0
9.00
Cochlear N-24
ACE
53.3
73.3
S5
Unknown
M
5.9
1.3
1.3
4.6
4.00
AB HiRes 90K
F120
33.3
75.0
S6
LVAS
F
8.0
2.3
2.3
5.7
6.00
MED-EL Pulsar
FSP
38.3
80.0
S7
LVAS
F
5.0
2.0
3.0
3.0
3.00
MED-EL Pulsar
FSP
40.0
83.3
S8
LVAS
M
7.2
5
2
2.2
2.00
AB HiRes 90K
F120
41.7
83.3
S9
Unknown
M
5.8
1.0
1.0
4.8
5.00
Cochlear N-24
ACE
35.0
88.3
S10
LVAS
M
6
1.5
1.5
4.5
3.30
AB HiRes 90K
F120
46.7
88.3
S11
LVAS
M
5.3
4.7
4.7
0.6
4.70
AB HiRes 90K
F120
35.0
90.0
S12
Unknown
M
8.1
7.0
2.0
1.1
3.00
MED-EL Pulsar
FSP
38.3
90.0
S13
LVAS
F
6.1
3.5
1.2
2.6
3.80
MED-EL Pulsar
FSP
48.3
91.7
S14
Unknown
M
5.9
3.1
3.1
2.8
1.00
MED-EL Pulsar
FSP
45.0
93.3
S15
LVAS
M
5.5
2
1
3.5
4.50
MED-EL Pulsar
FSP
40.0
96.7
S16
Unknown
F
5.6
2.1
2.1
3.5
2.00
Cochlear N-24
ACE
46.7
96.7
S17
Unknown
M
6.5
2.3
2.3
4.2
0.50
Cochlear N-24
ACE
53.3
96.7
S18
Unknown
F
5.2
1
1
4.2
1.00
MED-EL Pulsar
FSP
45.0
98.3
S19
Unknown
M
12.3
5.6
5.6
6.7
2.50
Cochlear N-24
ACE
56.7
98.3
S20
Unknown
M
5.8
3.3
3.3
2.5
1.00
Cochlear N-24
ACE
50.0
98.3
S21
Unknown
M
5.2
2.8
2.8
2.4
1.00
MED-EL Pulsar
FSP
36.7
98.3
S22
Unknown
M
5.2
3.1
3.1
2.1
5.00
MED-EL Pulsar
FSP
63.3
100.0
S23
LVAS
M
8.4
3.1
3.1
5.3
0.50
AB HiRes 90K
F120
56.7
105.0
S24
Unknown
F
5
1
4
3
4.00
Cochlear N-24
ACE
56.7
105.0
S25
Unknown
F
7.0
6.0
6.0
1.0
3.00
MED-EL Pulsar
FSP
58.3
106.7
S26
Unknown
M
5.2
1
1
4.2
0.60
MED-EL Pulsar
FSP
75.0
108.3
S27
Unknown
M
10.0
1.9
1.9
8.1
7.00
Cochlear N-24
ACE
70.0
108.3
S28
Unknown
M
5.2
3.0
3.0
2.2
1.50
Cochlear N-24
ACE
46.7
108.3
S29
Unknown
M
4.9
0.9
0.9
4
4.00
Cochlear N-24
ACE
65.0
110.0
S30
Unknown
M
6
2.6
2.6
3.4
1.00
MED-EL Pulsar
FSP
46.7
110.0
S31
Unknown
M
5.9
3.4
3.4
2.5
1.00
Cochlear N-24
ACE
60.0
110.0
S32
Unknown
M
6.8
2
2
4.8
1.00
Cochlear N-24
ACE
63.3
111.7
S33
Unknown
F
7.8
5.8
5.8
2.0
0.50
Cochlear N-24
ACE
61.7
111.7
S34
Unknown
M
5.1
0.9
0.9
4.2
1.00
MED-EL Pulsar
FSP
95.0
115.0
S35
Unknown
M
5.0
4.0
4.0
5.2
1.00
Cochlear N-24
ACE
66.7
115.0
AVE
6.5
2.9
2.7
3.5
2.7
51.1
96.0
SE
0.3
0.3
0.2
0.3
0.4
2.3
2.3
LAVS = large vestibular aqueduct syndrome; F = female; M = male; age at CI = age at cochlear implantation; dur deaf = duration of deafness; CI exp = CI experience; HA exp = HA experience; N-24 = Nucleus 24; AB = Advanced Bionics; ACE = advanced combination encoder; F120 = Fidelity 120; FSP=fine-structure processing; PTA = pure-tone average threshold across 0.5, 1.0, and 2.0 kHz. AVE = average; SE = standard error.
